CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study

Blood Advances - Tập 3 - Trang 1815-1825 - 2019
M. O'Dwyer1,2, R. Henderson1, S.D. Naicker3, M.R. Cahill4, P. Murphy5, V. Mykytiv6, J. Quinn5, C. McEllistrim1, J. Krawczyk1,2, J. Walsh2, E. Lenihan6, T. Kenny5, A. Hernando7, G. Hirakata7, I. Parker7, E. Kinsella7, G. Gannon2, A. Natoni3, K. Lynch3,8, A.E. Ryan3,8
1Department of Hematology, University Hospital Galway, Galway, Ireland
2Blood Cancer Network Ireland, Galway, Ireland
3Biomedical Sciences, National University of Ireland Galway, Galway, Ireland
4CancerResearch at UCC, University College Cork, Cork, Ireland
5Department of Hematology, Beaumont Hospital, Dublin, Ireland
6Department of Hematology, Cork University Hospital, Cork, Ireland
7Cancer Trials Ireland, Dublin, Ireland
8Discipline of Pharmacology & Therapeutics, School of Medicine, College of Medicine, Nursing, and Health Sciences, National University of Ireland Galway, Galway, Ireland

Tóm tắt

Abstract Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM). We conducted a phase 1b study to assess the safety and preliminary efficacy, as well as potential mechanisms of action, of DARA (16 mg/kg) in combination with a weekly schedule of subcutaneous bortezomib (1.3-1.5 mg/m2), cyclophosphamide (150-300 mg/m2), and dexamethasone (40 mg) (CyBorD DARA) as initial induction before autologous stem cell transplantation (ASCT). Eligible patients were ≤70 years of age with untreated MM requiring treatment and who lacked significant comorbidities. A total of 18 patients were enrolled. Their median age was 56 years (range, 32-66 years), and all patients had Eastern Cooperative Oncology Group performance status ≤1. The International Staging System stages were I, II, and III in 78%, 17%, and 6% of patients, respectively; 28% of patients had high-risk genetic features. There was no dose-limiting toxicity, and the incidence of grade 3 or 4 infection or neutropenia was <10%. On an intention-to-treat basis, 94% achieved ≥very good partial response with ≥complete response in 44% of patients. Among 14 of 15 patients who underwent ASCT and were evaluable for response, all 14 achieved at least very good partial response, with 8 (57%) of 14 achieving complete response. After ASCT, 10 (83%) of 12 patients in whom minimal residual disease analysis was possible were negative at a sensitivity of 10−5 (56% on intention-to-treat/whole study population) according to next-generation sequencing. Flow cytometry analysis of patient samples indicated CyBorD DARA induced activation of macrophage-mediated antibody-dependent cellular phagocytosis. This trial was registered at www.clinicaltrials.gov as #NCT02955810.

Tài liệu tham khảo

Palumbo, 2016, Daratumumab, bortezomib, and dexamethasone for multiple myeloma, N Engl J Med, 375, 754, 10.1056/NEJMoa1606038 Dimopoulos, 2018, Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX, Haematologica, 103, 2088, 10.3324/haematol.2018.194282 Mateos, 2018, Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma, N Engl J Med, 378, 518, 10.1056/NEJMoa1714678 Facon, 2019, Daratumumab plus lenalidomide and dexamethasone for untreated myeloma, N Engl J Med, 380, 2104, 10.1056/NEJMoa1817249 Moreau, 2017, Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, iv52, 10.1093/annonc/mdx096 Moreau, 2017, How I treat myeloma with new agents, Blood, 130, 1507, 10.1182/blood-2017-05-743203 Pallasch, 2014, Sensitizing protective tumor microenvironments to antibody-mediated therapy, Cell, 156, 590, 10.1016/j.cell.2013.12.041 Rigalou, 2016, Potentiation of anti-myeloma activity of daratumumab with combination of cyclophosphamide, lenalidomide or bortezomib via a tumor secretory response that greatly augments macrophage-induced ADCP, Blood, 128, 2101, 10.1182/blood.V128.22.2101.2101 Reeder, 2010, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma, Blood, 115, 3416, 10.1182/blood-2010-02-271676 Bringhen, 2010, Efficacy and safety of once-weekly bortezomib in multiple myeloma patients, Blood, 116, 4745, 10.1182/blood-2010-07-294983 Krejcik, 2016, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood, 128, 384, 10.1182/blood-2015-12-687749 Casneuf, 2017, Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma, Blood Adv, 1, 2105, 10.1182/bloodadvances.2017006866 Slevin, 2016, Infliximab selectively modulates the circulating blood monocyte repertoire in Crohn’s disease, Inflamm Bowel Dis, 22, 2863, 10.1097/MIB.0000000000000964 Weiner, 2012, Antibody-based immunotherapy of cancer, Cell, 148, 1081, 10.1016/j.cell.2012.02.034 Weiner, 2010, Monoclonal antibodies: versatile platforms for cancer immunotherapy, Nat Rev Immunol, 10, 317, 10.1038/nri2744 Nimmerjahn, 2005, Divergent immunoglobulin G subclass activity through selective Fc receptor binding, Science, 310, 1510, 10.1126/science.1118948 Gordon, 2017, PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity, Nature, 545, 495, 10.1038/nature22396 Naicker, 2018, Chronic kidney disease severity is associated with selective expansion of a distinctive intermediate monocyte subpopulation, Front Immunol, 9, 2845, 10.3389/fimmu.2018.02845 Herter, 2014, Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity, J Immunol, 192, 2252, 10.4049/jimmunol.1301249 Noy, 2014, Tumor-associated macrophages: from mechanisms to therapy [published correction appears in Immunity. 2014;41 (5):866], Immunity, 41, 49, 10.1016/j.immuni.2014.06.010 Willingham, 2012, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors, Proc Natl Acad Sci USA, 109, 6662, 10.1073/pnas.1121623109 Krawczyk, 2013, Cybord is an active, well tolerated, cost-effective induction regimen in newly diagnosed multiple myeloma—a single centre experience, Blood, 122, 5396, 10.1182/blood.V122.21.5396.5396 Attal, 2017, Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma, N Engl J Med, 376, 1311, 10.1056/NEJMoa1611750 Yimer, 2019, Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study, Br J Haematol, 185, 492, 10.1111/bjh.15806 Perrot, 2018, Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma, Blood, 132, 2456, 10.1182/blood-2018-06-858613 Kumar, 2016, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, 17, e328, 10.1016/S1470-2045(16)30206-6 Kuiper, 2015, Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System, Blood, 126, 1996, 10.1182/blood-2015-05-644039 Chari, 2017, Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study, Blood, 130, 3110 Panchabhai, 2016, Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma, Leukemia, 30, 951, 10.1038/leu.2015.191 Neri, 2017, Single cell resolution profiling defines the innate and adaptive immune repertoires modulated by daratumumab and IMiDs treatment in multiple myeloma (MM), Blood, 130, 123 Weiskopf, 2015, Macrophages are critical effectors of antibody therapies for cancer, MAbs, 7, 303, 10.1080/19420862.2015.1011450 van de Donk, 2018, CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance, Front Immunol, 9, 2134, 10.3389/fimmu.2018.02134 Abu Eid, 2016, Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed, Cancer Immunol Res, 4, 377, 10.1158/2326-6066.CIR-16-0048 Nijhof, 2016, Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma, Blood, 128, 2297, 10.1182/blood-2016-07-729236 Baz, 2016, Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma, Blood, 127, 2561, 10.1182/blood-2015-11-682518 Garderet, 2018, Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma, Blood, 132, 2555, 10.1182/blood-2018-07-863829 European Myeloma Network . https://www.myeloma-europe.org/trials/emn-18/. Accessed 3 June 2019.
Thông tin
Thông tin xuất bản

Blood Advances

Tập 3

1815-1825

Thông tin tác giả